About this episode
People with post-traumatic stress disorder (PTSD) may soon have a new treatment option: MDMA, the chemical found in ecstasy. In August, the Food and Drug Administration plans to decide whether MDMA-assisted therapy for PTSD will be approved for market based on years of research. But serious allegations of research misconduct may derail the approval timeline.
NPR science reporter Will Stone talks to host Emily Kwong about the clinical trials on MDMA-assisted therapy research and a recent report questioning the validity of the results.
Read Will's full story here.
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
NPR science reporter Will Stone talks to host Emily Kwong about the clinical trials on MDMA-assisted therapy research and a recent report questioning the validity of the results.
Read Will's full story here.
See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy
Get every episode summarized
Each time Short Wave publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Short Wave
A new investigation shows heat is even deadlier than we thought
Short Wave
Sep 4, 202614:45completed
The science of emotional regulation — and how to do it better
Short Wave
Sep 2, 202612:29pending
What can seashells teach us about the health of our oceans?
Short Wave
Sep 1, 202613:10pending
Football is here – and so is a new study on CTE
Short Wave
Aug 31, 202615:01pending